Evidence mapPaperPMID 36015105Full record

ReviewPharmaceuticals (Basel, Switzerland)2022

Resveratrol from Dietary Supplement to a Drug Candidate: An Assessment of Potential.

Shivani Khattar, Sauban Ahmed Khan, Syed Amir Azam Zaidi, Mahdi Darvishikolour, Uzma Farooq, Punnoth Poonkuzhi Naseef, Mohamed Saheer Kurunian, Mohammed Zaafar Khan, Athar Shamim, Mohd Masih Uzzaman Khan and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Effect and mechanisms of resveratrol in animal models of ischemic stroke: A systematic review and Bayesian meta-analysis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Pooled it
  3. Trial
  4. Trial
  5. Resveratrol-EnrichedNutrients · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Glyoxalase 1 Inducer,Antioxidants (Basel, Switzerland) · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Molecules (Basel, Switzerland) · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Shivani KhattarDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Sauban Ahmed KhanSchool of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Syed Amir Azam ZaidiSchool of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Mahdi DarvishikolourSchool of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Uzma FarooqDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Punnoth Poonkuzhi NaseefDepartment of Pharmaceutics, Moulana College of Pharmacy, Perinthalmanna, Kerala 679321, India.ORCID 0000-0001-9692-6323
Mohamed Saheer KurunianDepartment of Dental Technology, College of Applied Medical Sciences, King Khalid University, Abha 61421, Saudi Arabia.ORCID 0000-0003-3341-0914
Mohammed Zaafar KhanSchool of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Athar ShamimDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Mohd Masih Uzzaman KhanDepartment of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia.
Zeenat IqbalDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Mohd Aamir MirzaDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.ORCID 0000-0002-5780-7601
Jamia Hamdard · INQassim University · SAKing Khalid University · SAMoulana Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol (RVT) is a well known phyto-chemical and is widely used in dietary supplements and botanical products. It shows a wide range of pharmacological/beneficial effects. Therefore, it can be a potential candidate to be developed as phyto-pharmaceutical. Multiple diseases are reported to be treated by the therapeutic effect of RVT since it has antioxidant, anti-cancer activity and anti-inflammatory activities. It also has a major role in diabetes, arthritis, cardiac disorder and platelet aggregation etc. The major requirements are establishments regarding safety, efficacy profile and physicochemical characterization. As it is already being consumed in variable maximum daily dose, there should not be a major safety concern but the dose needs to be established for different indications. Clinical trials are also being reported in different parts of the world. Physicochemical properties of the moiety are also well reported. Moreover, due to its beneficial effect on health it leads to the development of some intellectual property in the form of patents.

Indexed as

antioxidantsanti-thrombogeniccarcinogenic and anti-agingcardioprotectiveneuroprotective

Identifiers

PMID36015105
PMCPMC9412308
OpenAlexW4289317688

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.